Signet invests in CRDMO Laxai

Laxai operates a drug substance manufacturing facility in Hyderabad.

  • The investment will be used to enhance Laxai’s capabilities and establish technical operations in the US
  • Tempus Law Associates and Richards, Layton & Finger served as legal advisors to Laxai while JSA Advocates & Solicitors and Sheppard, Mullin, Richter & Hampton LLP served as legal advisors to Signet
  • Signet invests in healthcare companies

Signet Healthcare Partners has acquired India-based Laxai, a contract research, development and manufacturing organization. No financial terms were disclosed.

Laxai operates a drug substance manufacturing facility in Hyderabad.

The investment will be used to enhance Laxai’s capabilities and establish technical operations in the U.S.

Signet Managing Director Nikhil Puri said in a statement, “Pharmaceutical outsourcing has become mission-critical within drug development. Our investment in Laxai is an attractive opportunity for SIGNET to partner with another CRO/CDMO business that was seeking an experienced partner to help execute its next phase of growth. We were attracted to LAXAI due to its vertically integrated offering, strong scientific capabilities, customer-centric approach, cost competitiveness, and management team strength.”

Tempus Law Associates and Richards, Layton & Finger served as legal advisors to LAXAI. JSA Advocates & Solicitors and Sheppard, Mullin, Richter & Hampton LLP served as legal advisors to Signet.

Headquartered in New York City, Signet invests in healthcare companies.